search
Back to results

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BI 10773 in Type II Diabetes Patients With Different Degrees of Renal Impairment

Primary Purpose

Diabetes Mellitus, Type 2

Status
Completed
Phase
Phase 1
Locations
Germany
Study Type
Interventional
Intervention
BI 10773
BI 10773
BI 10773
BI 10773
BI 10773
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria:

  1. Male and female subjects with type 2 diabetes
  2. Renally impaired male or female subjects
  3. Age 18 - 75 years
  4. BMI 18 - 34 kg/m2, at least 45 kg for females (Body Mass Index)
  5. Signed and dated written informed consent

Exclusion criteria:

  1. Significant gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders as judged by the investigator.
  2. Relevant gastrointestinal tract surgery
  3. Diseases of the central nervous system (such as epilepsy, seizures) or psychiatric disorders or relevant neurological disorders
  4. History of relevant orthostatic hypotension, fainting spells or blackouts; systolic blood pressure < 100 or > 160 mm Hg, diastolic blood pressure < 60 or > 100 mm Hg, pulse rate < 50 or > 100 1/min
  5. Chronic or relevant acute infections
  6. History of allergy/hypersensitivity (including drug allergies) that are deemed relevant to the trial as judged by the investigator
  7. Use within 10 days prior to administration or during the trial of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation. Co medication known to inhibit or induce P-glycoprotein or CYP3A is not allowed. Inhibitors of P-glycoprotein or CYP3A (cytochrom P3A) are e.g.

    • protease inhibitors, (e.g. ritonavir, lopinavir nelfinavir)
    • azole antimycotics, (itraconazole, ketoconazole, miconazole)
    • macrolid antibiotics, (clarithromycin, erythromycin)
    • amiodarone, cimetidine, diltiazem, fluvoxamine, mibefradil, nefazodone, verapamil, tacrolimus, quinidine, reserpine, cyclosporine A Inducers of P-gp or CYP3A are e.g. carbamazepine, phenobarbital, phenytoin, rifabutin, ri-fampin, St. John's wort, troglitazone. In dubious cases, a case by case decision will be made after consultation with the sponsor.

Sites / Locations

  • 1245.12.1 Boehringer Ingelheim Investigational Site
  • 1245.12.2 Boehringer Ingelheim Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

BI 10773 / Group 2

BI 10773 / Group 3

BI 10773 / Group 4

BI 10773 / Group 5

BI 10773 / Group 1

Arm Description

Single Dose Administration (type 2 diabetes and mild renal impairment)

Single Dose Administration (type 2 diabetes and moderate renal impairment)

Single Dose Administration (severe renal impairment 8)

Single Dose Administration (kidney failure)

Single Dose Administration (type 2 diabetes and normal renal function)

Outcomes

Primary Outcome Measures

AUC0-∞ (Area Under the Concentration Time Curve of the Analyte in Plasma Over the Time Interval From 0 to Infinity)
Area under the concentration time curve of the analyte in plasma over the time interval from 0 to infinity. The areas under the curve were calculated using the linear up/log down algorithm. If a drug concentration was equal to or higher than the preceding concentration, the linear trapezoidal method was used. If the drug concentration was smaller than the preceding concentration, the logarithmic method was used.
Cmax (Maximum Concentration of the Analyte in Plasma)
Maximum concentration of Empagliflozin in plasma

Secondary Outcome Measures

Time to Maximum Concentration of the Analyte in Plasma
Time from last dosing to maximum concentration of Empagliflozin in plasma (tmax)
Half-life and Mean Residence Time of the Analyte in Plasma
Terminal half-life of Empagliflozin (t1/2) and Mean residence time of Empagliflozin in the body
Terminal Rate Constant in Plasma
Terminal rate constant in plasma (Lz)
Apparent Clearance of the Analyte in the Plasma After Extravascular Administration
Apparent clearance of the analyte in the plasma after extravascular administration
Apparent Volume of Distribution During the Terminal Phase Lz
Apparent volume of distribution during the terminal phase Lz
AUC0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point. The areas under the curve were calculated using the linear up/log down algorithm. If a drug concentration was equal to or higher than the preceding concentration, the linear trapezoidal method was used. If the drug concentration was smaller than the preceding concentration, the logarithmic method was used.
Ae0-96 (Amount of Analyte That is Eliminated in Urine Over the Time Interval 0 to 96 h)
Amount of analyte that is eliminated in urine over the time interval 0-96 hours.
fe0-96 (Fraction of Analyte Excreted Unchanged in Urine From Time Points 0 to 96 Hours)
Fraction of analyte excreted unchanged in urine from time point 0-96 hours.
Renal Clearance of the Analyte in Plasma After Extravascular Administration
Renal Clearance of the Analyte in Plasma After Extravascular Administration for time interval 0-96 hours.
%AUCtz-∞ (Percentage of Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From the Time of the Last Quantifiable Data Point Extrapolated to Infinity)
Percentage of area under the concentration-time curve of the analyte in plasma over the time interval from the time of the last quantifiable data point extrapolated to infinity
Plasma Protein Binding
Plasma protein binding is the percent of analyte binding to the plasma protein, pre-dose plasma samples were spiked with Empa 1000 nmol/L. The standard deviation is actually the coefficient of variation.
Total Urinary Glucose Excretion (UGE)
Change from baseline in total urinary glucose excretion
Safety: Physical Examination, Vital Signs, ECG and Laboratory Measurements
Number of participants with clinically relevant findings in physical examination, Vital Signs, Clinically Significant Abnormalities in Electrocardiogram (ECG) and Significant Changes from Baseline Laboratory Measurements
Assessment of Tolerability by Investigator
Tolerability was assessed by the investigator based on adverse events and the laboratory evaluation.

Full Information

First Posted
July 15, 2013
Last Updated
July 11, 2014
Sponsor
Boehringer Ingelheim
search

1. Study Identification

Unique Protocol Identification Number
NCT01907113
Brief Title
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BI 10773 in Type II Diabetes Patients With Different Degrees of Renal Impairment
Official Title
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a Single 50 mg Dose of BI 10773 in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Type 2 Diabetes and Normal Renal Function in a Monocentric, Open-label, Parallel-group, Phase 1 Trial
Study Type
Interventional

2. Study Status

Record Verification Date
July 2014
Overall Recruitment Status
Completed
Study Start Date
July 2009 (undefined)
Primary Completion Date
December 2009 (Actual)
Study Completion Date
December 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim

4. Oversight

5. Study Description

Brief Summary
Assessment of the effect of normal and impaired kidney function on the pharmacokinetics, pharmacodynamics and safety of BI 10773

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
40 (Actual)

8. Arms, Groups, and Interventions

Arm Title
BI 10773 / Group 2
Arm Type
Experimental
Arm Description
Single Dose Administration (type 2 diabetes and mild renal impairment)
Arm Title
BI 10773 / Group 3
Arm Type
Experimental
Arm Description
Single Dose Administration (type 2 diabetes and moderate renal impairment)
Arm Title
BI 10773 / Group 4
Arm Type
Experimental
Arm Description
Single Dose Administration (severe renal impairment 8)
Arm Title
BI 10773 / Group 5
Arm Type
Experimental
Arm Description
Single Dose Administration (kidney failure)
Arm Title
BI 10773 / Group 1
Arm Type
Experimental
Arm Description
Single Dose Administration (type 2 diabetes and normal renal function)
Intervention Type
Drug
Intervention Name(s)
BI 10773
Intervention Description
oral administration
Intervention Type
Drug
Intervention Name(s)
BI 10773
Intervention Description
oral administration
Intervention Type
Drug
Intervention Name(s)
BI 10773
Intervention Description
oral administration
Intervention Type
Drug
Intervention Name(s)
BI 10773
Intervention Description
oral administration
Intervention Type
Drug
Intervention Name(s)
BI 10773
Intervention Description
oral administration
Primary Outcome Measure Information:
Title
AUC0-∞ (Area Under the Concentration Time Curve of the Analyte in Plasma Over the Time Interval From 0 to Infinity)
Description
Area under the concentration time curve of the analyte in plasma over the time interval from 0 to infinity. The areas under the curve were calculated using the linear up/log down algorithm. If a drug concentration was equal to or higher than the preceding concentration, the linear trapezoidal method was used. If the drug concentration was smaller than the preceding concentration, the logarithmic method was used.
Time Frame
1 hour (h) before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
Title
Cmax (Maximum Concentration of the Analyte in Plasma)
Description
Maximum concentration of Empagliflozin in plasma
Time Frame
1 hour (h) before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
Secondary Outcome Measure Information:
Title
Time to Maximum Concentration of the Analyte in Plasma
Description
Time from last dosing to maximum concentration of Empagliflozin in plasma (tmax)
Time Frame
1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
Title
Half-life and Mean Residence Time of the Analyte in Plasma
Description
Terminal half-life of Empagliflozin (t1/2) and Mean residence time of Empagliflozin in the body
Time Frame
1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
Title
Terminal Rate Constant in Plasma
Description
Terminal rate constant in plasma (Lz)
Time Frame
1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
Title
Apparent Clearance of the Analyte in the Plasma After Extravascular Administration
Description
Apparent clearance of the analyte in the plasma after extravascular administration
Time Frame
1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
Title
Apparent Volume of Distribution During the Terminal Phase Lz
Description
Apparent volume of distribution during the terminal phase Lz
Time Frame
1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
Title
AUC0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)
Description
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point. The areas under the curve were calculated using the linear up/log down algorithm. If a drug concentration was equal to or higher than the preceding concentration, the linear trapezoidal method was used. If the drug concentration was smaller than the preceding concentration, the logarithmic method was used.
Time Frame
1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
Title
Ae0-96 (Amount of Analyte That is Eliminated in Urine Over the Time Interval 0 to 96 h)
Description
Amount of analyte that is eliminated in urine over the time interval 0-96 hours.
Time Frame
24-0 h before drug administration and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96 hours after drug administration
Title
fe0-96 (Fraction of Analyte Excreted Unchanged in Urine From Time Points 0 to 96 Hours)
Description
Fraction of analyte excreted unchanged in urine from time point 0-96 hours.
Time Frame
24-0 h before drug administration and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96 hours after drug administration
Title
Renal Clearance of the Analyte in Plasma After Extravascular Administration
Description
Renal Clearance of the Analyte in Plasma After Extravascular Administration for time interval 0-96 hours.
Time Frame
24-0 h before drug administration and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96 hours after drug administration
Title
%AUCtz-∞ (Percentage of Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From the Time of the Last Quantifiable Data Point Extrapolated to Infinity)
Description
Percentage of area under the concentration-time curve of the analyte in plasma over the time interval from the time of the last quantifiable data point extrapolated to infinity
Time Frame
1 h before drug administration and 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00, 24:00, 36:00. 48:00, 72:00, 96:00 h after drug administration
Title
Plasma Protein Binding
Description
Plasma protein binding is the percent of analyte binding to the plasma protein, pre-dose plasma samples were spiked with Empa 1000 nmol/L. The standard deviation is actually the coefficient of variation.
Time Frame
1 h before drug administration and 1:30 and 3:00 h after drug administration
Title
Total Urinary Glucose Excretion (UGE)
Description
Change from baseline in total urinary glucose excretion
Time Frame
24-0 h before drug administration and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96 hours after drug administration (Interval 24-0 h before drug administration only for baseline UGE)
Title
Safety: Physical Examination, Vital Signs, ECG and Laboratory Measurements
Description
Number of participants with clinically relevant findings in physical examination, Vital Signs, Clinically Significant Abnormalities in Electrocardiogram (ECG) and Significant Changes from Baseline Laboratory Measurements
Time Frame
Drug administration until end-of-study-examination, 5 days
Title
Assessment of Tolerability by Investigator
Description
Tolerability was assessed by the investigator based on adverse events and the laboratory evaluation.
Time Frame
Drug administration until end-of-study-examination, 5 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Male and female subjects with type 2 diabetes Renally impaired male or female subjects Age 18 - 75 years BMI 18 - 34 kg/m2, at least 45 kg for females (Body Mass Index) Signed and dated written informed consent Exclusion criteria: Significant gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders as judged by the investigator. Relevant gastrointestinal tract surgery Diseases of the central nervous system (such as epilepsy, seizures) or psychiatric disorders or relevant neurological disorders History of relevant orthostatic hypotension, fainting spells or blackouts; systolic blood pressure < 100 or > 160 mm Hg, diastolic blood pressure < 60 or > 100 mm Hg, pulse rate < 50 or > 100 1/min Chronic or relevant acute infections History of allergy/hypersensitivity (including drug allergies) that are deemed relevant to the trial as judged by the investigator Use within 10 days prior to administration or during the trial of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation. Co medication known to inhibit or induce P-glycoprotein or CYP3A is not allowed. Inhibitors of P-glycoprotein or CYP3A (cytochrom P3A) are e.g. protease inhibitors, (e.g. ritonavir, lopinavir nelfinavir) azole antimycotics, (itraconazole, ketoconazole, miconazole) macrolid antibiotics, (clarithromycin, erythromycin) amiodarone, cimetidine, diltiazem, fluvoxamine, mibefradil, nefazodone, verapamil, tacrolimus, quinidine, reserpine, cyclosporine A Inducers of P-gp or CYP3A are e.g. carbamazepine, phenobarbital, phenytoin, rifabutin, ri-fampin, St. John's wort, troglitazone. In dubious cases, a case by case decision will be made after consultation with the sponsor.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Boehringer Ingelheim
Organizational Affiliation
Boehringer Ingelheim
Official's Role
Study Chair
Facility Information:
Facility Name
1245.12.1 Boehringer Ingelheim Investigational Site
City
Kiel
Country
Germany
Facility Name
1245.12.2 Boehringer Ingelheim Investigational Site
City
Neuss
Country
Germany

12. IPD Sharing Statement

Links:
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1245/1245.12_U10-2920-02.pdf
Description
Related Info
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1245/1245.12_Literature.pdf
Description
Related Info

Learn more about this trial

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BI 10773 in Type II Diabetes Patients With Different Degrees of Renal Impairment

We'll reach out to this number within 24 hrs